Literature DB >> 19754658

Drug eruption induced by IL-6 receptor inhibitor tocilizumab.

R Yoshiki, M Nakamura, Y Tokura.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19754658     DOI: 10.1111/j.1468-3083.2009.03437.x

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN: 0926-9959            Impact factor:   6.166


× No keyword cloud information.
  5 in total

Review 1.  Diagnoses and Management of Drug Hypersensitivity and Anaphylaxis in Cancer and Chronic Inflammatory Diseases: Reactions to Taxanes and Monoclonal Antibodies.

Authors:  Rafael Bonamichi-Santos; Mariana Castells
Journal:  Clin Rev Allergy Immunol       Date:  2018-06       Impact factor: 8.667

Review 2.  Tocilizumab-induced anaphylaxis in patients with adult-onset Still's disease and systemic juvenile idiopathic arthritis: a case-based review.

Authors:  Eun Hye Park; Eun Young Lee; Kichul Shin; Hyoun-Ah Kim
Journal:  Rheumatol Int       Date:  2019-10-09       Impact factor: 2.631

Review 3.  Immune-related adverse events of biological immunotherapies used in COVID-19.

Authors:  Daniela Baracaldo-Santamaría; Giovanna María Barros-Arias; Felipe Hernández-Guerrero; Alejandra De-La-Torre; Carlos-Alberto Calderon-Ospina
Journal:  Front Pharmacol       Date:  2022-08-25       Impact factor: 5.988

4.  'Toxic erythema' and eosinophilia associated with tocilizumab therapy in a COVID-19 patient.

Authors:  A Sernicola; G Carnicelli; M Di Fraia; C Chello; C Furlan; R Muharremi; G Paolino; T Grieco
Journal:  J Eur Acad Dermatol Venereol       Date:  2020-06-08       Impact factor: 9.228

5.  Diagnosis and management of the drug hypersensitivity reactions in Coronavirus disease 19: An EAACI Position Paper.

Authors:  Aslı Gelincik; Knut Brockow; Gülfem E Çelik; Inmaculada Doña; Cristobalina Mayorga; Antonino Romano; Özge Soyer; Marina Atanaskovic-Markovic; Annick Barbaud; Maria Jose Torres
Journal:  Allergy       Date:  2020-07-01       Impact factor: 14.710

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.